Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors

Sandrine Aspeslagh; Aurélien Marabelle; Jean-Charles Soria; Jean-Pierre Armand

doi:10.3978/j.issn.2304-3865.2015.12.06

Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors

Sandrine Aspeslagh, Aurélien Marabelle, Jean-Charles Soria, Jean-Pierre Armand

Medical Oncology

Research output: Contribution to journal › Scientific review › peer-review

7 Citations (Scopus)

Abstract

For decades, immunotherapy strategies have failed to succeed in lung cancer. However, the recent success of immune checkpoint inhibitors and the progress in the understanding of the immunobiology of lung cancer have changed this paradigm. Here we review ongoing clinical trials and recent results obtained with these novel lung cancer immunotherapies.

Original language	English
Article number	48
Journal	Chinese clinical oncology
Volume	4
Issue number	4
DOIs	https://doi.org/10.3978/j.issn.2304-3865.2015.12.06
Publication status	Published - Dec 2015

Keywords

Animals
Antineoplastic Agents/adverse effects
Cancer Vaccines/adverse effects
Humans
Immunologic Factors/adverse effects
Immunotherapy/adverse effects
Lung Neoplasms/drug therapy
Treatment Outcome

Access to Document

10.3978/j.issn.2304-3865.2015.12.06

Handle.net

Persistent link

Cite this

@article{16bcc5056cc44741bc6931e7d18d2c74,

title = "Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors",

abstract = "For decades, immunotherapy strategies have failed to succeed in lung cancer. However, the recent success of immune checkpoint inhibitors and the progress in the understanding of the immunobiology of lung cancer have changed this paradigm. Here we review ongoing clinical trials and recent results obtained with these novel lung cancer immunotherapies. ",

keywords = "Animals, Antineoplastic Agents/adverse effects, Cancer Vaccines/adverse effects, Humans, Immunologic Factors/adverse effects, Immunotherapy/adverse effects, Lung Neoplasms/drug therapy, Treatment Outcome",

author = "Sandrine Aspeslagh and Aur{\'e}lien Marabelle and Jean-Charles Soria and Jean-Pierre Armand",

year = "2015",

month = dec,

doi = "10.3978/j.issn.2304-3865.2015.12.06",

language = "English",

volume = "4",

journal = "Chinese clinical oncology",

issn = "2304-3865",

number = "4",

}

TY - JOUR

T1 - Upcoming innovations in lung cancer immunotherapy

T2 - focus on immune checkpoint inhibitors

AU - Aspeslagh, Sandrine

AU - Marabelle, Aurélien

AU - Soria, Jean-Charles

AU - Armand, Jean-Pierre

PY - 2015/12

Y1 - 2015/12

N2 - For decades, immunotherapy strategies have failed to succeed in lung cancer. However, the recent success of immune checkpoint inhibitors and the progress in the understanding of the immunobiology of lung cancer have changed this paradigm. Here we review ongoing clinical trials and recent results obtained with these novel lung cancer immunotherapies.

AB - For decades, immunotherapy strategies have failed to succeed in lung cancer. However, the recent success of immune checkpoint inhibitors and the progress in the understanding of the immunobiology of lung cancer have changed this paradigm. Here we review ongoing clinical trials and recent results obtained with these novel lung cancer immunotherapies.

KW - Animals

KW - Antineoplastic Agents/adverse effects

KW - Cancer Vaccines/adverse effects

KW - Humans

KW - Immunologic Factors/adverse effects

KW - Immunotherapy/adverse effects

KW - Lung Neoplasms/drug therapy

KW - Treatment Outcome

U2 - 10.3978/j.issn.2304-3865.2015.12.06

DO - 10.3978/j.issn.2304-3865.2015.12.06

M3 - Scientific review

C2 - 26730760

SN - 2304-3865

VL - 4

JO - Chinese clinical oncology

JF - Chinese clinical oncology

IS - 4

M1 - 48

ER -

Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this